Abstract: Human antibodies and antigen-binding portions of those antibodies that specifically bind extended Type I chain glycosphingolipids are provided.

Abstract: Human antibodies and antigen-binding portions of those antibodies that specifically bind extended Type I chain glycosphingolipids are provided.

Abstract: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate antigen can be Tn or sialyl-Tn.

Abstract: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate antigen can be Tn or sialyl-Tn.

Abstract: The present invention provides an SPR system and corresponding methods of use, for determining the presence or concentration of tumor-associated antigens in cancer patient samples. The SPR system may have multiple channels, with each channel having operably affixed thereto an antibody specific for a tumor-associated antigen, so as to allow detection of multiple tumor-associated antigens simultaneously. When a biological sample from a patient is applied to the SPR system, the presence of two or more tumor-associated antigens can be determined by measuring an SPR signal shift from each channel. The SPR system may detect the presence or concentration of a tumor-associated carbohydrate antigen, where the sensor surface contains affixed thereto an antibody specific for the glycosyl epitope, as well as an antibody specific for the polypeptide to which the carbohydrate antigen is naturally associated in cancer patients.

Abstract: Systematic chemical analysis of glycosphingolipid (GSL) fractions from large quantities of normal human neutrophils and HL60 cells failed to detect GSL's which are binding targets of selectin. A series of long-chain, unbranched polylactosamine GSL's with a terminally sialylated, internally polyfucosylated structure bind selectins.

Abstract: Systematic chemical analysis of glycosphingolipid (GSL) fractions from large quantities of normal human neutrophils and HL60 cells failed to detect GSL's containing an SLex structure. Instead, the binding target of E-selectin was revealed to be a series of long-chain, unbranched polylactosamine GSL's with a terminally sialylated, internally polyfucosylated structure, called, “myeloglycan”.

Abstract: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate antigen can be Tn or sialyl-Tn.

Abstract: A series of long chain, unbranched polylactosamine glycosphingolipids with terminally sialylated, internally polyfucosylated structures binds selectins.

Abstract: An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

Abstract: The invention relates to antibodies that specifically bind a myelorollin comprising an unbranched polylactosamine comprising at least 10 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except the penultimate N-acetylglucosamine residue. The invention also relates to a method of using such antibodies to inhibit E-selectin-dependent rolling of a cell on another cell, wherein one of the cells expresses a myelorollin that binds the antibodies.

Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.

Abstract: O-glycosylation and O-glycosylation extension inhibitors influence selectin-dependent interactions between cells and between cells and platelets.

Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory an anti-metastatic activity over related compounds.